Leqvio® (inclisiran) – Expanded indication
July 31, 2025 - Novartis announced the FDA approval of Leqvio (inclisiran), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).